$IRTC

Patterson Chad sold $884K of IRTC

Patterson Chad (CHIEF COMM & PRODUCT OFFICER) sold 7,093 shares of iRhythm Holdings, Inc. (IRTC) at $124.65 ($0.88M total) on 2026-08-10.

Original reporting
SEC EDGAR · Patterson Chad
Published Aug 11, 2026, 8:01 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 11, 2026, 8:03 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$IRTC
Neutral
medium confidence
Mentioned
$IRTC
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$IRTCNeutralLow
01

Why it matters

An officer’s open-market sale of $884K worth of shares is a sentiment datapoint, but it does not include any new operational, financial, or regulatory information about IRTC.

02

Market read

Traders may monitor for follow-on insider activity, but this filing alone is unlikely to drive a major repricing.

03

What to watch

Insider sales can be driven by diversification, taxes, or pre-existing personal liquidity needs; without additional context, the signal is weak.

Relevance 5/10Novelty 3/10Timing: filed 2026-08-11, sale dated 2026-08-10

Background

The article is an SEC Form 4 insider transaction disclosure for iRhythm Holdings, Inc. (IRTC).

Company-level read

Ticker impact

$IRTCNeutralMedium confidence
Context

IRTC disclosed a Form 4 showing officer Patterson Chad sold 7,093 shares for about $884K on 2026-08-10.

Expected impact

Likely limited near-term price impact; any effect would be sentiment-driven and small unless follow-on selling accelerates.

Evidence & confidence

The filing is primary-source and specific, but insider sales are often routine and the article provides no accompanying company performance or guidance change.

Market effects

No sector-level implications; this is company-specific insider transaction disclosure.

None indicated.

None indicated.

Counterpoint

The absence of a stated 10b5-1 plan could be interpreted as less “mechanical” selling, but the article still lacks evidence of distress or a broader sell signal.

Key entities

  • iRhythm Holdings, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • Patterson Chad

    Chief Commercial and Product Officer who sold shares.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$IRTCMedAI 9/10

iRhythm (IRTC) Q2 2026 Earnings Call Transcript

iRhythm (IRTC) reported Q2 2026 revenue of $224.2M, up 20.1% YoY, with gross margin at 72.8%. GAAP net loss was $0.4M, and adjusted EBITDA was $43.3M. Full-year revenue guidance is $880M to $890M and adjusted EBITDA margin 13% to 14%. The company agreed to acquire VitalConnect for about $287.5M and received a $50M Baxter settlement.

$IRTCMed

Why iRhythm (IRTC) Shares Are Trading Lower Today

iRhythm Technologies (IRTC) shares fell about 2.8% after Truist cut its price target to $18 from $160, keeping a Buy rating. The move followed iRhythm’s strong Q2 results, including $224.2M revenue (+20.1% YoY) and EPS of $0.58, and a raised FY revenue guidance midpoint to $885M.

$IRTCHighAI 9/10

iRhythm Q2 Earnings Beat Estimates on Volume Growth, '26 View Raised

iRhythm Holdings (IRTC) reported Q2 2026 adjusted EPS of 58 cents versus an adjusted loss of 32 cents a year earlier, beating the Zacks Consensus Estimate by 5900%. Revenue rose 20.1% to $224.2 million. Gross margin increased to 72.8%. Full-year 2026 revenue guidance was raised to $880 million-$890 million and adjusted EBITDA margin to 13%-14%.

$IRTCMedAI 8/10

IRTC Q2 Deep Dive: Product Portfolio Expansion and Margin Gains Highlight Quarter

iRhythm Technologies (IRTC) reported Q2 revenue of $224.2M, above analysts’ $219.2M estimate, and adjusted EPS of $0.58. Adjusted EBITDA was $43.3M versus $26.13M estimates. The company slightly raised full-year revenue guidance to $885M. It also agreed to acquire VitalConnect to expand cardiac monitoring offerings and expects margin gains from automation.